Autonomix Medical Selected for Best Innovation Competition at CRT 2026
MWN-AI** Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) announced its selection for the Best Innovation Competition at the Cardiovascular Research Technologies (CRT) 2026 conference, taking place in The Woodlands, TX. The company’s CEO, Brad Hauser, will present "Illuminating The Nervous System With Transvascular Precision-guided Technology" on March 9, 2026, spotlighting the innovative device designed to enhance nerve-targeted treatments.
This recognition underscores Autonomix's commitment to scientific innovation, technical differentiation, and clinical relevance in the medical device arena. The CRT Best Innovation Competition is known for showcasing transformative technologies that promise to advance patient care significantly. Hauser expressed that the selection validates their approach to precision-guided techniques for analyzing and treating nervous system conditions, highlighting the technology’s potential to offer unprecedented insights into peripheral nerve signaling.
Founded to revolutionize how diseases involving the nervous system are diagnosed and treated, Autonomix’s pioneering platform includes a catheter-based microchip sensing array. This technology aims to detect and differentiate neural signals with greater sensitivity than current methods, allowing for transvascular diagnosis and treatment across various indications. Initial applications are focused on addressing the debilitating pain associated with pancreatic cancer, a condition that currently lacks effective treatment solutions.
While the technology remains investigational and has not yet been authorized for marketing in the United States, Autonomix anticipates broad applications in cardiology, hypertension, and chronic pain management. The company's innovative direction positions it favorably amidst increasing interest in medical advancements for neurological conditions. As CRT 2026 approaches, stakeholders are eager to see how Autonomix's initiatives could reshape patient care in the future.
MWN-AI** Analysis
As Autonomix Medical, Inc. (NASDAQ: AMIX) prepares for its presentation at the Cardiovascular Research Technologies (CRT) conference, the selection for the Best Innovation Competition offers both validation and visibility for the company’s revolutionary technologies. Autonomix aims to transform how peripheral nervous system disorders, particularly debilitating pain from conditions like pancreatic cancer, are diagnosed and treated through its precision-guided, transvascular technology.
Investors should closely monitor several factors in the coming months. First, the outcome of the presentation, delivered by CEO Brad Hauser, could provide insights into potential investor sentiment. A successful presentation may not only enhance credibility but could also lead to increased institutional interest. If the technology is well-received, this could trigger upward momentum in AMIX's stock price.
Second, the competitive landscape of medical technologies is crucial. Autonomix’s capability to utilize microchip sensing arrays to obtain a deeper understanding of nerve signaling may differentiate it from existing treatments. Investors should evaluate how this positioning could resonate within the medical community and impact potential licensing agreements or partnerships.
Furthermore, ongoing clinical trials and their results will be pivotal. As the technology is still investigational and not yet marketed in the U.S., any advancements or successful trial results could serve as significant catalysts for share price appreciation. Conversely, investors should remain cognizant of the inherent risks associated with biopharmaceutical investments, such as regulatory hurdles and trial failures.
In summary, while Autonomix presents a compelling innovation story with promising market potential, astute investors should balance optimism with caution, keeping an eye on upcoming developments and industry trends that may affect the company's trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026.
The presentation will be delivered by Chief Executive Officer, Brad Hauser, on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET in the International Ballroom – West.
The CRT Best Innovation Competition highlights transformative technologies with the potential to meaningfully impact patient care. Selection for oral presentation reflects the program’s emphasis on scientific innovation, technical differentiation and clinical relevance.
“Being selected for CRT’s Best Innovation Competition is a strong validation of our precision-guided, transvascular approach to interrogating and treating the nervous system,” commented Brad Hauser, CEO of Autonomix. “Our technology is designed to provide physicians with unprecedented insight into peripheral nerve signaling.”
CRT is one of the world’s leading educational forums for interventional cardiovascular medicine, with Top Abstract podium selections representing the highest-scoring submissions based on scientific merit, innovation and clinical relevance. For more information, please visit the conference website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ**
How does Autonomix Medical Inc. (AMIX) plan to differentiate its transvascular precision-guided technology from existing nerve-targeted treatments in terms of clinical efficacy and patient outcomes?
What specific potential indications, beyond pancreatic cancer, is Autonomix Medical Inc. (AMIX) exploring for its catheter-based microchip sensing array in the upcoming trials?
Given the competitive landscape at the CRT Best Innovation Competition, what strategies does Autonomix Medical Inc. (AMIX) employ to ensure their technology receives the recognition it merits?
How does Autonomix Medical Inc. (AMIX) intend to address the risks and uncertainties mentioned in their forward-looking statements, particularly regarding the regulatory approval process for their novel technologies?
**MWN-AI FAQ is based on asking OpenAI questions about Autonomix Medical Inc. (NASDAQ: AMIX).
NASDAQ: AMIX
AMIX Trading
-0.61% G/L:
$0.3891 Last:
35,634 Volume:
$0.3945 Open:
